# PrEP-Pod-IVR (TDF-FTC/Placebo IVR 28 Day Crossover Study)

> **NCT03255915** · EARLY_PHASE1 · UNKNOWN · sponsor: **Oak Crest Institute of Science** · enrollment: 15 (actual)

## Conditions studied

- HIV Prevention

## Interventions

- **DRUG:** Tenofovir Disoproxil Fumarate (TDF)-Emtricitabine (FTC)
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT03255915
- **Lead sponsor:** Oak Crest Institute of Science
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-09-20
- **Primary completion:** 2020-09-30
- **Final completion:** 2025-12-31
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2023-11-03

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03255915

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03255915, "PrEP-Pod-IVR (TDF-FTC/Placebo IVR 28 Day Crossover Study)". Retrieved via AI Analytics 2026-06-07 from https://api.ai-analytics.org/clinical/NCT03255915. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*